Oruka Therapeutics Stock (NASDAQ:ORKA)

Ownership Financials Chart

Previous Close

$10.28

52W Range

$5.49 - $53.88

50D Avg

$10.21

200D Avg

$21.89

Market Cap

$391.25M

Avg Vol (3M)

$289.31K

Beta

0.42

Div Yield

$19.36 (185.22%)

ORKA Company Profile

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

28

IPO Date

-

Website

ORKA Performance

ORKA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-88.12M	$-7.30M	$-9.84M
Net Income	$-83.72M	$-5.34M	$-9.93M
EBITDA	$-82.23M	$-5.23M	$-9.81M
Basic EPS	$-4.99	$-4.44	$-8.27
Diluted EPS	$-4.99	$-4.44	$-8.27

Fiscal year ends in Dec 24 | Currency in USD